HK1100358A1 - 有關治療與胰島素相關的疾病的 及調質 - Google Patents

有關治療與胰島素相關的疾病的 及調質

Info

Publication number
HK1100358A1
HK1100358A1 HK07108497.4A HK07108497A HK1100358A1 HK 1100358 A1 HK1100358 A1 HK 1100358A1 HK 07108497 A HK07108497 A HK 07108497A HK 1100358 A1 HK1100358 A1 HK 1100358A1
Authority
HK
Hong Kong
Prior art keywords
gpr41
modulators
insulin
treatment
related disorders
Prior art date
Application number
HK07108497.4A
Other languages
English (en)
Inventor
James N Leonard
Zhi Liang Chu
Marc A Bruce
P Douglas Boatman
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of HK1100358A1 publication Critical patent/HK1100358A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07108497.4A 2004-11-03 2007-08-06 有關治療與胰島素相關的疾病的 及調質 HK1100358A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62486704P 2004-11-03 2004-11-03
PCT/US2005/039551 WO2006052566A2 (en) 2004-11-03 2005-11-01 Gpr41 and modulators thereof for the treatment of insulin-related disorders

Publications (1)

Publication Number Publication Date
HK1100358A1 true HK1100358A1 (zh) 2007-09-21

Family

ID=36336982

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108497.4A HK1100358A1 (zh) 2004-11-03 2007-08-06 有關治療與胰島素相關的疾病的 及調質

Country Status (12)

Country Link
US (1) US20080312277A1 (zh)
EP (1) EP1812080B1 (zh)
JP (2) JP5785354B2 (zh)
CN (1) CN101084018B (zh)
AU (1) AU2005305083B2 (zh)
CA (1) CA2584224A1 (zh)
ES (1) ES2498972T3 (zh)
HK (1) HK1100358A1 (zh)
IL (1) IL182574A (zh)
SG (1) SG170642A1 (zh)
TW (1) TWI440460B (zh)
WO (1) WO2006052566A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EA010023B1 (ru) 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
CN114681447B (zh) * 2020-12-30 2024-05-28 南京盛德瑞尔医药科技有限公司 一种戊酰胺类化合物作为谷氨酸脱氢酶抑制剂的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061359A2 (en) * 2000-02-18 2001-08-23 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
KR20030087001A (ko) * 2001-02-16 2003-11-12 제넨테크, 인크. Ｄｋｋ－１ 또는 그의 길항제가 관련된 치료법
ES2275887T3 (es) * 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
EP1498483A4 (en) * 2002-04-16 2005-12-07 Kyowa Hakko Kogyo Kk ENDOCRINE CELL LINES AND METHOD FOR THEIR USE
CA2497901A1 (en) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003267443A1 (en) * 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)

Also Published As

Publication number Publication date
AU2005305083A1 (en) 2006-05-18
JP5785354B2 (ja) 2015-09-30
EP1812080B1 (en) 2014-07-09
US20080312277A1 (en) 2008-12-18
IL182574A0 (en) 2008-04-13
CN101084018A (zh) 2007-12-05
TWI440460B (zh) 2014-06-11
JP2008518635A (ja) 2008-06-05
JP2013082748A (ja) 2013-05-09
WO2006052566A3 (en) 2006-10-12
AU2005305083B2 (en) 2012-02-02
CA2584224A1 (en) 2006-05-18
CN101084018B (zh) 2013-12-18
IL182574A (en) 2014-04-30
ES2498972T3 (es) 2014-09-26
TW200633707A (en) 2006-10-01
EP1812080A2 (en) 2007-08-01
SG170642A1 (en) 2011-05-30
WO2006052566A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
HK1190084A1 (zh) 用於預防和治療補體相關紊亂的 多肽
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en) Modulators of metabolism and the treatment of disorders related thereto
EP1926521A4 (en) DEVICES AND METHODS FOR RELEASING THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF SINUSITIS AND OTHER DISORDERS
IL230241A (en) Retinal history and methods of using them to treat visual irregularities
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
ZA200705540B (en) Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation
IL181706A0 (en) The treatment of inflammatory disorders and pain
PT2982372T (pt) Agentes moduladores do glutamato no tratamento de distúrbios mentais
EP1812077A4 (en) MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
EP1812009A4 (en) GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
GB0513413D0 (en) The treatment of inflammatory disorders and pain
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181101